Finance

Beta
Ask
Lists
GMAB:NASDAQ
Genmab A/S - ADR
$25.61
0.00%
(0.00) 1D
$25.67
+0.23% (+0.060)
Pre-market
Closed: Jun 22, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GMAB...
Mkt. cap
15.85B
Avg. vol.
2.06M
Volume
5.66K
P/E ratio
19.40
52-wk high
$35.43
52-wk low
$20.22
EPS
$1.32
Beta
0.85
Shares outstanding
623.53M
No. of employees
3K
Mkt. cap
15.85B
Avg. vol.
2.06M
Volume
5.66K
P/E ratio
19.40
52-wk high
$35.43
52-wk low
$20.22
EPS
$1.32
Beta
0.85
Shares outstanding
623.53M
No. of employees
3K
News stories
From sources across the web
Profile
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab Co., Ltd. in Suzhou, China. Genmab is listed on the Copenhagen Stock Exchange in Denmark, with American depositary receipts traded on the NASDAQ in the US. Wikipedia
About Genmab A/S - ADR
CEOJan G. J. van de Winkel
Employees3.09K
Founded1999
Headquarters-
SectorBiotechnology
Websitegenmab.com
Analyst Ratings
Based on 9 analysts giving stock ratings to GMAB in the past 3 months
Strong Buy
Buy
7
Hold
2
Sell
0
12 month forecast
Based on 9 Wall Street analysts offering 12 month price targets for GMAB in the last 3 months.
Highest
Current $25.61
$40.00 (+56.19%)
Average
$35.07 (+36.94%)
Lowest
$30.50 (+19.09%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$38.00
+48.4%
06/23/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
06/15/2026
Kalpit Patel
Wolfe Research
Buy
Maintained
$32.00
+25%
06/14/2026
Gregory Renza
Truist Financial
Buy
Maintained
-
-
06/12/2026
Eva Fortea Verdejo
Wells Fargo
Buy
Reiterated
$40.00
+56.2%
06/01/2026
Asthika Goonewardene
Truist Financial
Buy
Initiated
$40.00
+56.2%
05/27/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$40.00
+56.2%
05/25/2026
Yaron Werber
TD Cowen
Hold
Maintained
$32.00
+25%
05/07/2026
Judah Frommer
Morgan Stanley
Hold
Maintained
$33.00
+28.9%
05/08/2026
Rajan Sharma
Goldman Sachs
Buy
Upgraded
$30.50
+19.1%
04/22/2026
Benjamin Jackson CFA
Jefferies
Buy
Initiated
$41.50
+62%
02/17/2026
Last report
May 7, 2026
Fiscal period
Q1 2026
EPS / Est. (DKK)
- / DKK 8.23
Revenue / Est. (DKK)
5.69B / 5.65B
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in DKK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in DKK
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Revenue
4.68B
4.14B
5.40B
5.54B
Cost of goods sold
-
-
-
273.00M
Cost of revenue
-
-
-
273.00M
Research and development expenses
-
-
-
2.28B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
-
-
865.00M
Operating expense
-
-
-
3.15B
Total operating expenses
-
-
-
3.42B
Operating income
-
-
-
2.12B
Other non operating income
-
-
-
-
EBT including unusual items
-
-
-
1.72B
EBT excluding unusual items
-
-
-
1.59B
Income tax expense
-
-
-
453.00M
Effective tax rate
-
-
-
26.35%
Other operating expenses
-
-
-
-
Net income
-
-
-
1.27B
Net profit margin
-
-
-
22.85%
Earnings per share
9.67
-
-
19.81
Interest and investment income
-
-
-
162.00M
Interest expense
-
-
-
-18.00M
Net interest expenses
-
-
-
144.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
2.20B
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer